| SARS-CoV-2 immunogenicity at the crossroads #MMPMID32401346Karamloo F; Konig RAllergy 2020[Jul]; 75 (7): 1822-1824 PMID32401346show ga
ä|*Immunogenicity, Vaccine[MESH]|Angiotensin-Converting Enzyme 2[MESH]|Antibodies, Neutralizing/immunology[MESH]|Antibodies, Viral/immunology[MESH]|Betacoronavirus/genetics/*immunology[MESH]|COVID-19[MESH]|Coronavirus Infections/*prevention & control/virology[MESH]|Cross Reactions[MESH]|Humans[MESH]|Mutation Rate[MESH]|Pandemics/*prevention & control[MESH]|Peptidyl-Dipeptidase A/metabolism[MESH]|Pneumonia, Viral/*prevention & control/virology[MESH]|SARS-CoV-2[MESH]|Spike Glycoprotein, Coronavirus/*immunology/metabolism[MESH]
DeepDyve Pubget Overpricing |
|